Wire · opportunities
Asundexian Is the First Factor XIa Inhibitor to Gain FDA Approval
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 10 November 2026 · Fusion42 review
The FDA approved asundexian, the first oral factor XIa inhibitor, for secondary prevention of noncardioembolic ischemic stroke in adults, following positive trial results showing reduced stroke recurrence without increased major bleeding. Bayer plans distribution soon, but high list price may slow uptake despite patient assistance programs.
This Wire brief sits within Fusion42's coverage of Biotech, and 15 sources have reported it between 9 Nov 2026 and 19 Nov 2026.
◆ ◆ The Wire takeaway
Stroke drug developers should target safe oral anticoagulants that lower bleeding risk as FDA approval now favours factor XIa inhibitors like asundexian. You need to build payer-friendly access models as price concerns could block uptake.
◆ Coverage
15 sources · first reported 9 Nov 2026 · latest 19 Nov 2026
◆ Related on Wire
◆ Topics